EGFR and non-small cell lung carcinoma: In the FLAURA trial, median overall survival (OS) was 38.6 months in the osimertinib group and 31.8 months in the gefitinib or erlotinib group [10], with the advent of EGFR-TKIs improving prognosis in the EGFR-mutated NSCLC.